Literature DB >> 23702172

Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment.

Kerry L Dierberg1, Richard E Chaisson.   

Abstract

Tuberculosis (TB) is the leading cause of opportunistic infection and mortality among HIV-infected persons. Screening for symptoms of TB in people with HIV infection, use of isoniazid preventive therapy for those with latent TB infection, earlier diagnosis and treatment of active TB disease, and early initiation of antiretroviral therapy are essential for controlling the spread of TB. Treatment of HIV-related TB is complicated by overlapping drug toxicities and drug-drug interactions between antiretroviral therapy and anti-TB therapy and risk for development of immune reconstitution inflammatory disease. This review provides an overview of the prevention and treatment of TB in HIV-infected persons.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23702172      PMCID： PMC3746796          DOI： 10.1016/j.ccm.2013.02.003

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   2.878


  54 in total

1.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

2.  New regimens to prevent tuberculosis in adults with HIV infection.

Authors:  Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

3.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

Review 4.  Tuberculosis.

Authors:  Stephen D Lawn; Alimuddin I Zumla
Journal:  Lancet       Date:  2011-03-21       Impact factor: 79.321

5.  Concordance of a positive tuberculin skin test and an interferon gamma release assay in bacille Calmette-Guérin vaccinated persons.

Authors:  C S Mahan; D F Johnson; C Curley; F van der Kuyp
Journal:  Int J Tuberc Lung Dis       Date:  2011-02       Impact factor: 2.373

6.  Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.

Authors:  M Estee Török; Nguyen Thi Bich Yen; Tran Thi Hong Chau; Nguyen Thi Hoang Mai; Nguyen Hoan Phu; Pham Phuong Mai; Nguyen Thi Dung; Nguyen Van Vinh Chau; Nguyen Duc Bang; Nguyen Anh Tien; N H Minh; Nguyen Quang Hien; Phan Vuong Khac Thai; Doan The Dong; Do Thi Tuong Anh; Nguyen Thi Cam Thoa; Nguyen Ngoc Hai; Nguyen Ngoc Lan; Nguyen Thi Ngoc Lan; Hoang Thi Quy; Nguyen Huy Dung; Tran Tinh Hien; Nguyen Tran Chinh; Cameron Paul Simmons; Menno de Jong; Marcel Wolbers; Jeremy James Farrar
Journal:  Clin Infect Dis       Date:  2011-06       Impact factor: 9.079

7.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Jonathan E Kaplan; Constance Benson; King K Holmes; John T Brooks; Alice Pau; Henry Masur
Journal:  MMWR Recomm Rep       Date:  2009-04-10

8.  Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; Robert J Wilkinson; Chelsea Morroni; Dominique J Pepper; Kevin Rebe; Molebogeng X Rangaka; Tolu Oni; Gary Maartens
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

9.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321

10.  Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.

Authors:  Stephen D Lawn; Sophie V Brooks; Katharina Kranzer; Mark P Nicol; Andrew Whitelaw; Monica Vogt; Linda-Gail Bekker; Robin Wood
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069
View more
  5 in total

Review 1.  Economic challenges associated with tuberculosis diagnostic development.

Authors:  Colleen F Hanrahan; Maunank Shah
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2014-04-28       Impact factor: 2.217

2.  Clinical Correlates and Drug Resistance in HIV-Infected and -Uninfected Pulmonary Tuberculosis Patients in South India.

Authors:  Chandy Sara; Heylen Elsa; Mishra Baijayanti; Ekstrand Maria Lennartsdotter
Journal:  World J AIDS       Date:  2016-09-09

3.  A pilot study to determine the occurrence of concomitant diseases and drug intake in patients on antituberculosis therapy.

Authors:  Ratinder Jhaj; Shweta Sharma; Mohammed Sabir; Arun Kokane
Journal:  J Family Med Prim Care       Date:  2018 Mar-Apr

4.  BCG and BCG/DNAhsp65 vaccinations promote protective effects without deleterious consequences for experimental autoimmune encephalomyelitis.

Authors:  Sofia Fernanda Gonçalves Zorzella-Pezavento; Clara Pires Fujiara Guerino; Fernanda Chiuso-Minicucci; Thais Graziela Donegá França; Larissa Lumi Watanabe Ishikawa; Ana Paula Masson; Célio Lopes Silva; Alexandrina Sartori
Journal:  Clin Dev Immunol       Date:  2013-10-29

5.  Added value of QuantiFERON TB-gold in-tube for detecting latent tuberculosis infection among persons living with HIV/AIDS.

Authors:  Josiane Maria Oliveira Souza; Maria do Socorro Nantua Evangelista; Anete Trajman
Journal:  Biomed Res Int       Date:  2014-05-29       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.